RGEN Repligen Corporation

Repligen Corporation to Present at Upcoming September Conferences

Repligen Corporation to Present at Upcoming September Conferences

WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences.

  • The Wells Fargo Healthcare Conference, being held September 3 – 5 in Boston. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at 8:00 a.m. ET on Thursday, September 4, 2025.
  • The Deutsche Bank Healthcare Summit, being held September 10 – 11 in New York. Jason Garland, Chief Financial Officer, will participate in 1x1 meetings on September 10.
  • The Bank of America Global Healthcare Conference, being held September 23 – 25 in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at 6:35 a.m. ET/11:35 a.m. British Summer Time on Thursday, September 25, 2025.

A live webcast of the conference presentations will be accessible through Repligen’s  website at , and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at , and follow us on .

Repligen Contact:

Jacob Johnson

VP, Investor Relations

781-419-0204

 



EN
22/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Repligen Corporation

 PRESS RELEASE

Repligen Corporation to Present at Upcoming September Conferences

Repligen Corporation to Present at Upcoming September Conferences WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences. The Wells Fargo Healthcare Conference, being held September 3 – 5 in Boston. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at 8:00 a.m. ET on Thursday, September 4, 2025.The Deutsche Bank Healthcare Summit, being held September 10 – 1...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 16, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Repligen Corp: 1 director

A director at Repligen Corp bought 1,800 shares at 112.128USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Repligen Announces Strategic Partnership with Novasign to Further Adva...

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign’s machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in Novasign to help scale and expand operations. Through this collaboration, Novasign’s uni...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch